China Biopharmaceutical announced that the recombinant fusion protein in the national class 1 innovative drug IM-101 injection developed by Zhengda Tianqing, a subsidiary of the group, has obtained clinical trial approval from the China National Drug Administration and is intended to be used to treat chronic hepatitis B.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.